{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:44:58Z","timestamp":1780674298958,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>This meta-analysis assessed the efficacy and safety of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in the treatment of complicated urinary tract infection (cUTI)\/acute pyelonephritis (APN).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, Web of Science, EBSCO (Elton B. Stephens Co.), Cochrane Library, Ovid MEDLINE, and Embase databases were accessed until November 21, 2019. In this meta-analysis, only randomized controlled trials comparing the treatment efficacy of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations with other antibiotics for cUTI\/APN in adult patients were included. The outcomes included the clinical and microbiological responses, and risk of adverse events (AEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, the experimental group treated with a novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination and the control group comprised 1346 and 1376 patients, respectively. No significant difference in the clinical response rate at test-of-cure was observed between the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination and comparators among the microbiological modified intent-to-treat population (89.1% vs 88.3%, OR, 1.04; 95% confidence interval [CI], 0.76\u20131.42; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a28%) and the microbiologically evaluable population (95.2% vs 94.7%, OR, 1.12; 95% CI, 0.68\u20131.84; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a0%). Additionally, the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination was associated with a better microbiological response at test-of-cure than the comparators among the microbiological modified intent-to-treat population (74.4% vs 68.5%, OR, 1.34; 95% CI, 1.04\u20131.72; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a45%) and microbiologically evaluable population (80.1% vs 72.5%, OR, 1.49; 95% CI, 1.06\u20132.10; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a58%). Finally, the risk of AEs associated with the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination was similar to that associated with the comparators (treatment-emergent adverse events [TEAE], OR, 1.04; 95% CI, 0.87\u20131.23; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a19%; serious AEs, OR, 1.21; 95% CI, 0.82\u20131.76; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a0%; treatment discontinuation for drug-related TEAE, OR, 077; 95% CI, 0.38\u20131.56, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a5%). The all-cause mortality did not differ between the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination and comparators (OR, 1.19; 95% CI, 0.37\u20133.81; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a0%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The clinical and microbiological responses of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in the treatment of cUTI\/APN are similar to those of other available antibiotics. These combinations also share a safety profile similar to that of other antibiotics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019960","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:36:25Z","timestamp":1588970185000},"page":"e19960","source":"Crossref","is-referenced-by-count":6,"title":["Novel \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections"],"prefix":"10.1097","volume":"99","author":[{"given":"Li-Chin","family":"Lu","sequence":"first","affiliation":[{"name":"School of Management, Putian University, Putian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Peng","family":"Chang","sequence":"additional","affiliation":[{"name":"Yijia Pharmacy, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Huan","family":"Lan","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Hsing","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, Chi-Mei Hospital, Chia Li"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Orthopedic, Chi Mei Medical Center, Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5]]},"reference":[{"key":"R1-20240308","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic Shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"},{"key":"R2-20240308","article-title":"In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance United States 2015\u20132017","author":"Karlowsky","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"R3-20240308","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/IDR.S203572","article-title":"Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016-2017 update of the Chinese SMART study","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"R4-20240308","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12879-018-3405-1","article-title":"Carbapenem susceptibilities of Gram-negative pathogens in intra-abdominal and rinary tract infections: updated report of SMART 2015 in China","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Infect Dis"},{"key":"R5-20240308","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation beta-Lactam\/beta-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20240308","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-019-01112-1","article-title":"New drugs for multidrug-resistant gram-negative organisms: time for stewardship","volume":"79","author":"Jean","year":"2019","journal-title":"Drugs"},{"key":"R7-20240308","doi-asserted-by":"crossref","first-page":"105858","DOI":"10.1016\/j.ijantimicag.2019.11.015","article-title":"The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and urinary tract infections - a meta-analysis of randomized controlled trials","volume":"55","author":"Cheng","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R8-20240308","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/jcm8101650","article-title":"Meropenem-vaborbactam in the treatment of acute bacterial infections","volume":"8","author":"Lai","year":"2019","journal-title":"J Clin Med"},{"key":"R9-20240308","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/antibiotics8040255","article-title":"Ceftazidime-avibactam versus meropenem for the treatment of complicated intra-abdominal infections","volume":"8","author":"Tan","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"R10-20240308","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"R11-20240308","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jgar.2019.09.016","article-title":"In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical Isolates of meropenem-non-susceptible Pseudomonas aeruginosa: a two-center study","volume":"20","author":"Mirza","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"R12-20240308","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17)","volume":"75","author":"Spiliopoulou","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R13-20240308","article-title":"In vitro activity of the new beta-lactamase inhibitors relebactam and vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20240308","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/IDR.S150447","article-title":"Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae","volume":"11","author":"Petty","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R15-20240308","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R16-20240308","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"R17-20240308","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R18-20240308","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R19-20240308","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R20-20240308","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"R21-20240308","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R22-20240308","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a phase 3 clinical trial programme for the treatment of complicated urinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R23-20240308","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"R24-20240308","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015\u200ameropenem\/vaborbactam surveillance programme","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R25-20240308","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13756-018-0435-9","article-title":"In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae","volume":"7","author":"Zhang","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"R26-20240308","article-title":"In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20240308","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00533-18","article-title":"In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:10:27Z","timestamp":1709928627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019960"}},"subtitle":["A meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":27,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019960","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}